Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has filed a new patent application for its DSM (Degradable Starch Microspheres) technology with the European Patent Office (EPO). The patent application covers an expanded use of DSM products in the embolization of tumors and is intended to support the initiation of new development projects, in line with Magle Group’s expansion strategy.

The patent application covers microspheres that are complexed to a radioactive metal, to be used in dosimetry planning before the treatment of liver malignancies through embolization.
 
“Magle Group sees great potential for DSM-based products in tumor embolization, and the new patent application will further strengthen the rationale for expanding our portfolio of development projects within this underserved and commercially attractive area,“ says Camilla Gummesson, Director of R&D at Magle Group. 
 
Provided the patent application is approved, it will provide intellectual property protection in relevant territories until 2043.

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

Magle Group applies for extended patent protection of its DSM technology in Europe

© Modular Finance, source Nordic Press Releases